A Phase Ib/II Study of PEP503 (Radioenhancer) With Radiotherapy, in Combination With Concurrent Chemotherapy for Patients With Locally Advanced or Unresectable Rectal Cancer

Trial Profile

A Phase Ib/II Study of PEP503 (Radioenhancer) With Radiotherapy, in Combination With Concurrent Chemotherapy for Patients With Locally Advanced or Unresectable Rectal Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Oct 2016

At a glance

  • Drugs NBTXR 3 (Primary) ; Capecitabine; Fluorouracil
  • Indications Adenocarcinoma; Rectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors PharmaEngine
  • Most Recent Events

    • 11 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top